T-type and L-type voltage-gated calcium channels (LTCC/TTCC)

T-type and L-type calcium channels are distinct classes of voltage-gated ion channels that facilitate the entry of calcium ions into cells, serving as critical regulators of physiological processes. L-type channels (Long-lasting, high-voltage activated) are primarily found in cardiac and smooth muscle, where they mediate excitation-contraction coupling and vascular tone, as well as in endocrine cells for hormone secretion (Wikipedia, 2024) [1.3.3]. T-type channels (Transient, low-voltage activated) are prominent in the heart's pacemaker cells and various neurons, where they influence rhythmic firing, action potential generation, and pain transmission (NIH, 2022) [1.3.2]. These channels are major therapeutic targets for cardiovascular diseases like hypertension and angina, and neurological conditions such as absence epilepsy and chronic pain (Patsnap, 2024) [1.4.3]. Pharmacological agents include selective L-type blockers like amlodipine, selective T-type blockers like ethosuximide, and dual blockers like mibefradil (NIH, 1999) [1.5.5]. Structurally, these channels are composed of a pore-forming alpha-1 subunit (CaV1.1-1.4 for L-type and CaV3.1-3.3 for T-type) along with auxiliary subunits that modulate channel kinetics and trafficking (Wikipedia, 2024) [1.3.3]. In the cardiovascular system, L-type channels are the primary targets of dihydropyridines, while T-type channels are increasingly recognized for their role in pathological cardiac remodeling and heart failure (Encyclopedia MDPI, 2022) [1.4.4]. In the central nervous system, T-type channels in the thalamus are essential for generating the spike-and-wave discharges characteristic of absence seizures (NIH, 2008) [1.2.2]. Emerging research also highlights the potential of T-type channel inhibitors as novel treatments for various cancers due to their role in cell cycle progression and proliferation (Cancer Res, 2018) [1.2.4]. While highly effective, targeting these channels requires careful management of side effects such as peripheral edema and potential drug-drug interactions, particularly with agents that inhibit metabolic enzymes like CYP3A4 (Johnson Francis, 2024) [1.1.1].

Other names

Voltage-gated calcium channelsCaV1 and CaV3 channelsHigh-voltage and low-voltage activated calcium channelsDihydropyridine-sensitive and transient calcium channels

The mechanism of action involves the binding of drugs to the alpha-1 subunit of the calcium channel, which inhibits the inward flow of calcium ions during membrane depolarization. This blockade leads to the relaxation of vascular smooth muscle (vasodilation), decreased myocardial contractility (negative inotropy), and slowed cardiac conduction (negative dromotropy) for L-type channels. For T-type channels, blockade stabilizes the resting membrane potential and reduces the frequency of rhythmic firing in neurons and pacemaker cells, providing anticonvulsant and anti-arrhythmic effects (Patsnap, 2024) [1.4.3, 1.4.5].